Vasodilator Stress CMR and All-Cause Mortality in Stable Ischemic Heart Disease: A Large Retrospective Registry

Victor Marcos-Garces1, Jose Gavara2, Jose V Monmeneu3

  • 1Department of Cardiology, Hospital Clinico Universitario de Valencia, Valencia, Spain.

Insights

Extensive ischemic burden measured by vasodilator stress cardiovascular magnetic resonance (CMR) is linked to higher mortality in stable ischemic heart disease (SIHD). Revascularization benefits only patients with significant ischemia.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Medical Diagnostics

Background:

  • Stable ischemic heart disease (SIHD) patient outcomes are influenced by ischemic burden.
  • The prognostic value of vasodilator stress cardiovascular magnetic resonance (CMR) for all-cause mortality in SIHD is not fully understood.
  • The impact of revascularization on mortality based on ischemic burden requires further investigation.

Purpose of the Study:

  • To explore the association between ischemic burden, assessed by vasodilator stress CMR, and all-cause mortality in SIHD patients.
  • To evaluate the effect of revascularization on all-cause mortality in SIHD patients, considering the extent of ischemia.

Main Methods:

  • A retrospective analysis of 6,389 patients with known or suspected SIHD who underwent vasodilator stress CMR.
  • Ischemic burden was quantified using a 17-segment model based on stress first-pass perfusion imaging.
  • Revascularization's impact on all-cause mortality was assessed in matched cohorts within 3 months of CMR.

Main Results:

  • Increased ischemic burden (per segment) was independently associated with higher all-cause mortality (HR 1.04; p < 0.001).
  • Over a median follow-up of 5.75 years, 11% of patients died.
  • Revascularization reduced mortality only in patients with extensive ischemia (>5 segments) (10% vs. 24%; p = 0.01).

Conclusions:

  • Extensive ischemic burden identified by vasodilator stress CMR predicts increased long-term all-cause mortality in SIHD.
  • Revascularization demonstrates a protective effect on mortality, but primarily in a select group of patients with significant ischemia.
  • These findings suggest a tailored approach to revascularization based on CMR-derived ischemic burden may be beneficial.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
242
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.6K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
649
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
128